l-Glutamine and the Dawn of Combination Therapy for Sickle Cell Disease

In 2017, the U.S. Food and Drug Administration approved l -glutamine (USAN, glutamine) for the prevention of acute vaso-occlusive pain events in persons with sickle cell disease who are older than 5 years of age — only the first drug to be approved for this indication in the 20 years since the appro...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 379; no. 3; pp. 292 - 294
Main Author Minniti, Caterina P
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 19.07.2018
Subjects
Anemia, Sickle Cell
Combined Modality Therapy
Disclosure
FDA approval
Glutamine
Humans
Oxidative stress
Sickle cell disease
United States > US
Online AccessGet full text

Cover

More Information
Summary:In 2017, the U.S. Food and Drug Administration approved l -glutamine (USAN, glutamine) for the prevention of acute vaso-occlusive pain events in persons with sickle cell disease who are older than 5 years of age — only the first drug to be approved for this indication in the 20 years since the approval of hydroxyurea. The much awaited data that supported this landmark approval are available for review in the article by Niihara et al. in this issue of the Journal . 1 In a phase 3, randomized, double-blind, placebo-controlled trial involving 230 patients (5 to 58 years old) with homozygous hemoglobin S . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMe1800976